5122 On Other Exchanges
Symbol
Exchange
Tokyo

okamoto industries inc (5122) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OKAMOTO INDUSTRIES INC (5122)
\

Related News

No related news articles were found.

okamoto industries inc (5122) Related Businessweek News

View More BusinessWeek News

okamoto industries inc (5122) Details

Okamoto Industries, Inc. manufactures and sells convenience products in Japan and internationally. The company produces a range of plastic films, decorative films, and industrial materials; condoms, household and general-purpose gloves, and adhesive tapes; and rubber tire chains for winter roads, rubber icepacks, rubber bands, injection-molding boots, and others. It also provides BodiHeat, a heat pad for back pain, stiff neck/shoulders, aching joints, and chills. The company was founded in 1934 and is headquartered in Tokyo, Japan.

2,765 Employees
Last Reported Date: 06/27/19
Founded in 1934

okamoto industries inc (5122) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

okamoto industries inc
Okamoto Industries, Inc., Annual General Meeting, Jun 27, 2019

Okamoto Industries, Inc., Annual General Meeting, Jun 27, 2019, at 10:00 Tokyo Standard Time. Location: head office building the first floor Place Place 27-29, Hongo 3-chome Bunkyo-ku Tokyo Japan Agenda: To consider business report for the 123rd term (from april 1, 2018 to march 31, 2019); and to consider consolidated calculation Matter of co.

Okamoto Launches VivaGel Condom in Japan

Starpharma announced that the VivaGel® condom has been launched in Japan under Okamoto's highly successful Zero Zero Three (003) brand. This is the first condom with antiviral coating in Japan and will also carry Starpharma's VivaGel® brand. The VivaGel® condom is a product based on innovative Australian technology. It is the only condom of its type, providing barrier protection and incorporating the proprietary compound, astodrimer sodium (SPL7013) in the condom lubricant. SPL7013 has been proven in laboratory studies to inactivate up to 99.9% of HIV, HSV and HPV. Starpharma is eligible to receive royalties based on sales of the VivaGel® condom and also revenue on supply of SPL7013 active. Starpharma received first receipts from Okamoto in April.

Okamoto Industries, Inc. to Report Fiscal Year 2019 Results on May 09, 2019

Okamoto Industries, Inc. announced that they will report fiscal year 2019 results on May 09, 2019

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

5122 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 5122.
View Industry Companies
 

Industry Analysis

5122

Industry Average

Valuation 5122 Industry Range
Price/Earnings 15.4x
Price/Sales 1.1x
Price/Book 1.6x
Price/Cash Flow 15.8x
TEV/Sales 0.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact OKAMOTO INDUSTRIES INC, please visit www.okamoto-inc.jp. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.